About 100 reports

  • OF CONTENTS

In December 2017, the FDA approved Bristol-Myers Squibb' s PD-## inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Journal of Global Infectious Diseases; ##(##): ##- ##.

  • Hepatitis
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • FINANCIAL

EACH PARTY, THROUGH ITS REPRESENTATIVES, SHALL HAVE ONE (##) VOTE ON THE JSC AND EACH SUBCOMMITTEE.

  • Hepatitis
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

(USA) ##.

  • Antiviral
  • Hepatitis
  • United States
  • World
  • Market Shares

It can be added into normal Immune Globulin for manufacture of a medicament effective against an autoimmune disease, immunodeficiency syndrome, etc..

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.
  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • GLOBAL HEPATITIS THERAPEUTICS MARKET

OTHER CAUSES INCLUDE HEAVY CONSUMPTION OF ALCOHOL, TOXINS, MEDICATIONS, AND OTHER INFECTIONS SUCH AS HIV AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.
  • 3.6 SOVALDI / HARVONI SALES & FORECAST

The Sovaldi/ Harvoni sales was the second biggest drugs sales in the universe just short of the US$ ##. ## Billion in sales recorded in 2014 by AbbVie' s autoimmune disease drug Humira, which is believed to be the world' s topselling pharmaceutical.

  • Hepatitis
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • PERKINELMER

IT IS THE WORLD LEADER IN IN VITRO DIAGNOSTICS AND MEDICINES FOR CANCER AND TRANSPLANTATION; IT IS ALSO ACTIVE IN SEVERAL OTHER MAJOR THERAPEUTIC AREAS INCLUDING AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, VIROLOGY, METABOLIC DISORDERS AND DISEASES OF THE CENTRAL NE

  • Hepatitis
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Driven by an obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease, affecting one-third of the Western world.

  • Hepatitis
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • Tiziana Life Sciences PLC

ORIBASE PHARMA HAS THE CO-PROPERTY AND EXCLUSIVE RIGHT OF EXPLOITATION OF INVENTIONS OF THE ANTIBODIES THAT WILL BE DEVELOPED IN THE FIELD OF DIAGNOSIS AND TREATMENT OF HUMAN CANCERS, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES.

  • Hepatitis
  • Oncology
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.
  • Jun 12, 2017: Tiziana Life Sciences Strengthens Unique Research Focus by Appointing Dr Kunwar Shailubhai as Chief Executive Officer

Driven by an obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease, affecting one-third of the Western world.

  • Hepatitis
  • Therapy
  • United States
  • Company Financials
  • Tiziana Life Sciences PLC
  • PIPELINE BY NOVARTIS AG, H1 2018

Its drug candidate, PRN##, a reversible covalent BTK inhibitor, is in Phase ## development for pemphigus vulgaris, an orphan autoimmune disease and PRN## is in Phase ## for solid tumors.

  • Cancer
  • Hepatitis
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Johnson & Johnson - Discovery, 2016

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • Hepatitis
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States

The presentation focused on Can-Fite' s CF## for the treatment of autoimmune and anti-inflammatory diseases.

  • Cardiovascular Drug
  • Hepatitis
  • Therapy
  • World
  • Can-Fite BioPharma Ltd.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.
  • R&D Progress

Reasons for premature withdrawal included patient refusal to continue or withdrew consent (## patients), disease remission (## patient) and death due to an acute infection (## patient).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • REPLICor Inc.

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • SWOT Analysis - Overview

The company' s ddRNAi technology holds significant potential to address various disease conditions in the therapeutic domain of cancer (lung, liver, and breast), neurological diseases (huntingdons, dementia, and glioblastoma), infectious diseases (HIV/ AIDS, Hepati

  • Biopharmaceutical
  • Hepatitis
  • RNA Interference
  • Therapy
  • Benitec Biopharma Limited
  • Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma

Its other clinical programmes include TZLS-##, a human engineered anti-human CD## antibody intended for the treatment of autoimmune and inflammatory diseases.

  • Cancer
  • Hepatitis
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.

It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases.

  • Cancer
  • Hepatitis
  • United States
  • Product Initiative
  • Exelixis, Inc.

Results Overall in BRCA positive patients (Parts ## and ##, n=##), disease control rate is ##. ##% and overall response rate (ORR) is ##% (Part ## ORR ##% and Part ## ##%).

  • Hepatitis
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

These cells are functional and suppress the development of experimental spontaneous autoimmune diseases.

  • Hepatitis
  • Therapy
  • World
  • Product Initiative
  • Shenogen Pharma Group
  • SPRING BANK PHARMACEUTICALS INC

NA : Not Available Source: Global Markets Direct RGT-## - DRUG PROFILE and/ or IL-## and/ or IL-##β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies,

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Rigontec GmbH

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • United States
  • World
  • Product Initiative
  • Eisai Co., Ltd.

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Hepatitis
  • Oncology
  • United States
  • Product Initiative
  • Exelixis, Inc.

Plexxikon announced in January that enrollment started for the first of two Phase ## clinical trials with PLX##, a novel, oral, targeted and highly selective Fms kinase inhibitor for the treatment of autoimmune diseases such as RA.

  • Hepatitis
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

OSE' s Effi-## is in preclinical development and targets autoimmune diseases and transplantation.

  • Autoimmune Disease
  • Hepatitis
  • United States
  • World
  • Product Initiative

Only ## patient had progressive disease.

  • Hepatitis
  • Hospital
  • Therapy
  • United States
  • Product Initiative

Monoclonal Antibody for Autoimmune Disease - Drug Profile Monoclonal Antibody for Autoimmune Disease Ono Pharmaceutical Co., Ltd.

  • Hepatitis
  • Lung Cancer
  • Pharmaceutical
  • United States
  • Ono Pharmaceutical Co., Ltd.